ranibizumab + triamcinolone acetonide
Phase 2/3UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Uveal Melanoma
Conditions
Uveal Melanoma
Trial Timeline
Sep 1, 2009 → —
NCT ID
NCT00811200About ranibizumab + triamcinolone acetonide
ranibizumab + triamcinolone acetonide is a phase 2/3 stage product being developed by Novartis for Uveal Melanoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT00811200. Target conditions include Uveal Melanoma.
What happened to similar drugs?
0 of 2 similar drugs in Uveal Melanoma were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
15
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00811200 | Phase 2/3 | UNKNOWN |
Competing Products
20 competing products in Uveal Melanoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pembrolizumab + Lenvatinib | Eisai | Phase 2 | 39 |
| Selumetinib, 100mg + Selumetinib, 125mg + Selumetinib, 150mg + Selumetinib, 175mg + Selumetinib, 200mg + Selumetinib, 225mg | AstraZeneca | Phase 1 | 29 |
| Pembrolizumab + Entinostat | Merck | Phase 2 | 35 |
| Pembrolizumab + Olaparib | Merck | Phase 2 | 42 |
| Pembrolizumab 25 MG/1 ML Intravenous Solution | Merck | Phase 2 | 39 |
| AEB071 | Novartis | Phase 1 | 29 |
| LXS196 + LXS196 and HDM201 | Novartis | Phase 1 | 21 |
| DYP688 | Novartis | Phase 1/2 | 36 |
| RAD001 (Everolimus) and Pasireotide (SOM230) LAR | Novartis | Phase 2 | 35 |
| Crizotinib | Pfizer | Phase 2 | 35 |
| Dacarbazine + Sunitinib | Pfizer | Phase 2 | 35 |
| AEB071 + MEK162 | Pfizer | Phase 1/2 | 24 |
| Binimetinib + Belinostat | Pfizer | Phase 2 | 39 |
| Ipilimumab + Nivolumab | Bristol Myers Squibb | Phase 1 | 29 |
| Nivolumab + Relatlimab | Bristol Myers Squibb | Phase 2 | 35 |
| ipilimumab + Nivolumab | Bristol Myers Squibb | Phase 2 | 35 |
| ZIV-Aflibercept + Cemiplimab | Sanofi | Phase 2 | 42 |
| Ziv-Aflibercept | Regeneron Pharmaceuticals | Phase 2 | 27 |
| XmAb®23104 + Yervoy® (ipilimumab) | ICON plc. | Phase 1 | 26 |
| IDE196 + Binimetinib + Crizotinib | IDEAYA Biosciences | Phase 1/2 | 33 |